GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...

At the time, GSK sold Zantac as a prescription drug in the UK but it stopped as a precaution following the US decision. GSK and other sellers of the medicine have always maintained that ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion drug caused cancers. The British drug giant has agreed to pay up to $2.2bn ...

One PBM billed an employer more than $200 for a single generic ranitidine prescription, for which it paid the dispensing pharmacy $15. In another instance, the PBM billed $80 for generic atenolol ...

As the FDA’s investigation continued, they ultimately decided to issue an involuntary recall, pulling all prescription and over-the-counter heartburn drugs containing ranitidine from the market ...